These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 17148544

  • 1. Changes in macrophage function after rituximab treatment in patients with rheumatoid arthritis.
    Toubi E, Kessel A, Slobodin G, Boulman N, Pavlotzky E, Zisman D, Rozenbaum M, Rosner I.
    Ann Rheum Dis; 2007 Jun; 66(6):818-20. PubMed ID: 17148544
    [Abstract] [Full Text] [Related]

  • 2. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement.
    Alessandri C, Bombardieri M, Papa N, Cinquini M, Magrini L, Tincani A, Valesini G.
    Ann Rheum Dis; 2004 Oct; 63(10):1218-21. PubMed ID: 15361374
    [Abstract] [Full Text] [Related]

  • 3. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse.
    Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JC.
    Arthritis Rheum; 2006 Mar; 54(3):723-32. PubMed ID: 16508933
    [Abstract] [Full Text] [Related]

  • 4. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis.
    Quartuccio L, Fabris M, Salvin S, Atzeni F, Saracco M, Benucci M, Cimmino M, Morassi P, Masolini P, Pellerito R, Cutolo M, Puttini PS, De Vita S.
    Rheumatology (Oxford); 2009 Dec; 48(12):1557-9. PubMed ID: 19789202
    [Abstract] [Full Text] [Related]

  • 5. Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis.
    De Rycke L, Verhelst X, Kruithof E, Van den Bosch F, Hoffman IE, Veys EM, De Keyser F.
    Ann Rheum Dis; 2005 Feb; 64(2):299-302. PubMed ID: 15166003
    [Abstract] [Full Text] [Related]

  • 6. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis.
    Cambridge G, Leandro MJ, Edwards JC, Ehrenstein MR, Salden M, Bodman-Smith M, Webster AD.
    Arthritis Rheum; 2003 Aug; 48(8):2146-54. PubMed ID: 12905467
    [Abstract] [Full Text] [Related]

  • 7. Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment.
    Lal P, Su Z, Holweg CT, Silverman GJ, Schwartzman S, Kelman A, Read S, Spaniolo G, Monroe JG, Behrens TW, Townsend MJ.
    Arthritis Rheum; 2011 Dec; 63(12):3681-91. PubMed ID: 22127691
    [Abstract] [Full Text] [Related]

  • 8. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.
    Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, Gabay C, van Riel PL, Nordström DC, Gomez-Reino J, Pavelka K, Tomsic M, Kvien TK, van Vollenhoven RF.
    Ann Rheum Dis; 2011 Sep; 70(9):1575-80. PubMed ID: 21571731
    [Abstract] [Full Text] [Related]

  • 9. Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis.
    Braun-Moscovici Y, Markovits D, Zinder O, Schapira D, Rozin A, Ehrenburg M, Dain L, Hoffer E, Nahir AM, Balbir-Gurman A.
    J Rheumatol; 2006 Mar; 33(3):497-500. PubMed ID: 16511906
    [Abstract] [Full Text] [Related]

  • 10. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
    van der Linden MP, van der Woude D, Ioan-Facsinay A, Levarht EW, Stoeken-Rijsbergen G, Huizinga TW, Toes RE, van der Helm-van Mil AH.
    Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
    [Abstract] [Full Text] [Related]

  • 11. B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study.
    Sellam J, Hendel-Chavez H, Rouanet S, Abbed K, Combe B, Le Loët X, Tebib J, Sibilia J, Taoufik Y, Dougados M, Mariette X.
    Arthritis Rheum; 2011 Apr; 63(4):933-8. PubMed ID: 21225699
    [Abstract] [Full Text] [Related]

  • 12. IgM-rheumatoid factor, anti-cyclic citrullinated peptide, and anti-citrullinated human fibrinogen antibodies decrease during treatment with the tumor necrosis factor blocker infliximab in patients with rheumatoid arthritis.
    Vis M, Bos WH, Wolbink G, Voskuyl AE, Twisk JW, Van de Stadt R, Hamann D, Dijkmans BA, Lems WF.
    J Rheumatol; 2008 Mar; 35(3):425-8. PubMed ID: 18322974
    [Abstract] [Full Text] [Related]

  • 13. Blockade of tumour necrosis factor {alpha} significantly alters the serum level of IgG- and IgA-rheumatoid factor in patients with rheumatoid arthritis.
    Yazdani-Biuki B, Stadlmaier E, Mulabecirovic A, Brezinschek R, Tilz G, Demel U, Mueller T, Brickmann K, Graninger WB, Brezinschek HP.
    Ann Rheum Dis; 2005 Aug; 64(8):1224-6. PubMed ID: 16014683
    [Abstract] [Full Text] [Related]

  • 14. Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody.
    Mikuls TR, O'Dell JR, Stoner JA, Parrish LA, Arend WP, Norris JM, Holers VM.
    Arthritis Rheum; 2004 Dec; 50(12):3776-82. PubMed ID: 15593224
    [Abstract] [Full Text] [Related]

  • 15. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis.
    Chen HA, Lin KC, Chen CH, Liao HT, Wang HP, Chang HN, Tsai CY, Chou CT.
    Ann Rheum Dis; 2006 Jan; 65(1):35-9. PubMed ID: 15975966
    [Abstract] [Full Text] [Related]

  • 16. Apoptotic effect of rituximab on peripheral blood B cells in rheumatoid arthritis.
    Szodoray P, Alex P, Dandapani V, Nakken B, Pesina J, Kim X, Wallis GL, Wilson PC, Jonsson R, Centola M.
    Scand J Immunol; 2004 Jan; 60(1-2):209-18. PubMed ID: 15238091
    [Abstract] [Full Text] [Related]

  • 17. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment.
    Higashida J, Wun T, Schmidt S, Naguwa SM, Tuscano JM.
    J Rheumatol; 2005 Nov; 32(11):2109-15. PubMed ID: 16265687
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.
    Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T.
    N Engl J Med; 2004 Jun 17; 350(25):2572-81. PubMed ID: 15201414
    [Abstract] [Full Text] [Related]

  • 19. [The role of anti-cyclic citrullinated peptide (anti-CCP) antibodies in serologic diagnosis and evaluation of disease activity in rheumatoid arthritis].
    Aridoğan BC, Kaya S, Savaş S, Cetin ES, Akkuş S, Demirci M.
    Mikrobiyol Bul; 2008 Oct 17; 42(4):669-74. PubMed ID: 19149089
    [Abstract] [Full Text] [Related]

  • 20. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis.
    Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC.
    Arthritis Rheum; 2006 Feb 17; 54(2):613-20. PubMed ID: 16447239
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.